Samba II PCR testing for COVID-19 in an unselected cohort of pregnant women in the UK

Ruiling Xu
Rosie Hospital Neonatal Unit

Tara Alicia Pauley
Rosie Maternity Hospital

Hannah Missfelder-Lobos
Rosie Maternity Hospital

Richard John Haddon
Cambridge University Hospitals NHS Foundation Trust

Ravindra Kumar Gupta
Cambridge University: University of Cambridge

Hsu Phern Chong (✉️ hsu.chong@nhs.net)
Rosie Maternity Hospital  https://orcid.org/0000-0002-4662-3882

Research article

Keywords: Tertiary hospital, infection, COVID-19, IQR, NP, OP

DOI: https://doi.org/10.21203/rs.3.rs-103715/v1

License: ©  This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

**OBJECTIVE:** Asymptomatic carriage of COVID-19 in pregnant women has been reported and could lead to outbreaks in maternity units. We sought to ascertain the impact of rapid isothermal nucleic acid based testing for COVID-19 in an unselected cohort of pregnant women attending our maternity unit. We also assessed the correlation between community prevalence and asymptomatic carriage.

**DESIGN:** Retrospective cohort analysis and literature review

**SETTING:** Tertiary hospital in Cambridge, UK

**POPULATION:** Pregnant women (with gestation age between 12-42 weeks) admitted to a single maternity unit over a 4-week period (07/05/2020-06/06/2020)

**METHODS:** Data were collected using computerised hospital records. Literature searches were performed across multiple repositories. COVID-19 prevalence was extracted from online repositories.

**RESULTS:** NP and OP swabs were obtained from 457/465 women during the study period (98%). The median turnaround time for results was 5.3 hours (interquartile range (IQR) 2.6-8.9 hours). 92% of results were returned within 24 hours. In our cohort, only one woman tested positive, giving a screen positive rate of 0.22% (1/457; 95% confidence interval: 0.04-1.23%). One woman who tested negative developed a fever postnatally following discharge but was lost to follow-up. From our literature review, we did not find any correlation between asymptomatic carriage in pregnant women and the reported regional prevalence of COVID-19.

**CONCLUSIONS:** Testing using the SAMBA-II machine was acceptable to the vast majority of pregnant women requiring admission and had a low turnaround time. Asymptomatic carriage is low, but not correlated to community prevalence rates. Screening pregnant women on admission will remain an important component in order to minimise nosocomial infection.

Introduction

The World Health Organization (WHO) characterized Coronavirus disease 2019 (COVID-19) as a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in March 2020.[1] The first case series was described by Huang et al[2] where 41 patients were admitted to Jin Yin-Tan Hospital in Wuhan, China. 98% of the 41 confirmed cases had fever and 76% had a dry cough, all developed pneumonia. Deep sequencing of lower respiratory tract samples identified the viral genome to be from the coronavirus family and this was named (COVID-19). Cellular access is gained through a spike protein that binds to the angiotensin-converting enzyme 2 receptor (ACE2), and viral uptake is promoted by the type 2 transmembrane serine protease (TMPRSS2).[3] Lauer reported a median 5.7 days to fever onset (CI 4.9-6.8 days), and 97.5% of cases had a fever within 12.5 days (CI 8.2-17.7 days of exposure).[4] Importantly, COVID-19 often takes a prolonged disease course with viral load in throat and nose declining after the first week as antibody titres rise.[5] This can result in nucleic acid testing becoming negative after the first week, though neutralisation and SARS-CoV-2 antibodies are readily detectable in nearly all cases[6]. Asymptomatic carriage of COVID-19 was estimated to be 15% (95% CI 10 to 22%) in general population[7] and Sutton et al[8] reported that positive rate of 13.7% (29/210) among asymptomatic group and 87.9% (29/33) of pregnant women infected with SARS-CoV-2 were asymptomatic at presentation.

Identification of asymptomatic pregnant women with COVID-19 is important for several reasons. Firstly, identification of asymptomatic carriers would allow changes in the pathway of care so as to prevent nosocomial infections, reducing the risk of asymptomatic transmission to other pregnant women and also to healthcare workers (HCW). Testing also enables early isolation and rationalisation of personal protective equipment (PPE). Thirdly, identification of viral carriage could allow closer monitoring both during and after delivery, consideration of low molecular heparin for prophylaxis of venous thromboembolism, and longer term follow-up.

SAMBA II is an isothermal point of care nucleic acid amplification based platform with a detection limit of around 250 genome copies/ml.[9] It has previously been clinically validated in parallel with standard reverse transcription polymerase chain reaction (RT-PCR) with sensitivity and specificity of 96.9 % (95% CI 0.838-0.999) and 99.1% (0.953-0.999) for COVID-19, respectively.[10] The median time to result has been significantly reduced from 26.4 hours (IQR 21.4 to 31.4) for the standard lab RT-PCR test to 2.6 hours (IQR 2.3 to 4.8) for SAMBA II SARS-CoV-2 test.[11]

**Aims**

The aims of this paper are two-fold: to ascertain the incidence of asymptomatic carriage in our maternity unit using a rapid diagnostic testing platform; and to assess if the rate of carriage of COVID-19 in asymptomatic pregnant women correlated with peak local prevalence.

**Methods**

*Cohort study*

Cambridge University Hospitals NHS Foundation Trust (CUH) covers a large geographical area with a total population of approximately 5 million people in the east of England. The Rosie Maternity Hospital is part of CUH, with an annual delivery rate of approximately 5500 women. All admissions to the Rosie Maternity Hospital were offered a nasopharyngeal (NP) and oropharyngeal (OP) swab for COVID-19. All staff members received training prior to obtaining
swabs. Samples were processed using the SAMBA II machine (Diagnostics for the Real World, Chesterford, UK).[12, 13] Data were extracted for population demographics and symptomatology. Symptoms were defined as fever and or cough. Patients who were asymptomatic were defined as women who lacked a fever and/or cough from the time of testing to discharge. Turnaround time was defined as the time the swab was collected, to the time a result was uploaded onto the electronic hospital record. Where time entries were missing, electronic hospital notes were retrieved to check for a record of sample collection and availability of results. These were computed separately. Our study was registered as a service evaluation project and ethical approval was not required.

Literature review

We conducted a literature search from PubMed, Cochrane COVID-19 trials for published studies, MedRxiv for pre-prints and an unofficial online repository on 15/05/2020 and updated on 07/08/2020. Where datasets from the same institution were replicated in more than one publication, but with a larger sample size or longer duration, the publication with the largest sample size and/or duration was selected. Data were extracted for case definition, diagnostic test employed, duration of follow up, gestational age at the time of testing and turnaround time. In order to assess if the prevalence of COVID-19 positive symptomatic and asymptomatic pregnant women correlated with local prevalence rates, we extracted local population COVID-19 prevalence rates for each of the included studies from open source repositories (Supplementary information). Data were analysed using GraphPad Prism version 5.00 for Windows, GraphPad Software, San Diego California USA, www.graphpad.com. Data were extracted by two reviewers (RX and HC), and disagreements were resolved by discussion with a 3rd reviewer (TP).

Results

SAMBA-II results

During the period 07/05 - 06/06 (4 weeks) 465 women attended the Rosie Maternity Hospital for obstetric indications. NP and OP swabs were obtained from 457/465 women upon admission (98%). 18 (3.84%) women had more than one swab taken either due to prolonged inpatient admission beyond 7 days, or reattendance within the 4 week period. Self-reported ethnicity was available for 99.5% of women. The majority of our population consisted of White British, Irish or European ancestry (407/465, 87.5%) and this is reflective of the local population in Cambridgeshire. The median gestational age at the time of the admission swab was 39 weeks (Interquartile range (IQR) 37-40 weeks). Six women (1.3%) attended in the postnatal period due to obstetric concerns. The median duration of inpatient stay for all patients was two days (IQR 1-3). The median duration of follow-up in the postnatal period was 5 days (IQR 3-9).

None of the women had a cough on admission. 37/465 women developed a fever either during labour or following delivery (7.9%). All 37 women had a negative result on admission, and the fever was attributed to an obstetric cause. Two women were admitted with breathlessness on a background of cardiac disease. One woman developed symptoms of fever or sore throat four days after delivery. Advice from Public Health England at the time was to contact a national helpline and she was lost to follow up.

Only one woman in our cohort tested positive over this four-week interval. This woman had neither cough nor fever on admission, but had symptoms of altered taste and smell four weeks prior to her admission. To ensure that this was a true positive, swabs were repeated (but not included in our current analyses for TAT) until she tested negative. As this patient remained symptom-free during admission, she would be the only true asymptomatic COVID-19, giving an asymptomatic carriage rate of 0.22% (1/457; 95% confidence interval: 0.04-1.23%). Knowledge of her results enabled HCW to convert from using standard surgical masks, plastic aprons and gloves to full personal protective equipment when caring for this patient.

Result turnaround times (TAT) were verified and available for 432/457 (94.5%) samples. The median TAT was 5.3 hours (IQR 2.6-8.9) (Figure 1). 424/457 (92.7%) were returned within 24 hours. Where sample turnaround times were absent, these were due to an underestimation of turnaround times rather than a delay in sample processing. This information was gleaned from verbatim entries in the patient records regarding the sample obtained, and the results lacked a fever and/or cough from the time of testing to discharge. Turnaround time was defined as the time the swab was collected, to the time a result was uploaded onto the electronic hospital record. Where time entries were missing, electronic hospital notes were retrieved to check for a record of sample collection and availability of results. These were computed separately. Our study was registered as a service evaluation project and ethical approval was not required.

Literature review

Four hundred and seven articles were screened for title and abstract and 46 full-text articles assessed for inclusion. 17 universal screening studies[14–30] (Table 1) were selected to assess if the prevalence of COVID-19 positive pregnant women correlated with local prevalence rates as these papers fulfilled our prespecified criteria above.

We found a correlation between the test positivity with the regional background prevalence rates of COVID-19. There was a direct correlation between the number of confirmed cases at the peak (R²=0.41, p=0.0053) (Figure 2B) and end of the study period with those who tested positive (R²=0.48, p=0.002) (Figure 2C), but not with the number of confirmed cases at the start of the study period (R²=0.004, p=0.82) (Figure 2A). There was no correlation between the proportions of asymptomatic pregnant carriers with background infection rates (Figure 3).

Only three papers reported turnaround time. Breslin et al[31] reported an average of 8 hours for 43 women screened [Conventional PCR, (New York, New York)] and LaCourse et al[25] reported a median turnaround time of 2.5 hours for rapid testing [DiaSorin Simplexa (MDX Liaison) EUA assay, n=82 women]
and 7.1 hours for routine PCR (Seattle, Washington). London et al[22] reported an average turnaround time of 5 hours using GeneXpert PCR in a cohort of 75 women (Brooklyn, New York).

**Discussion**

*Main findings:*

Our work summarises existing literature on universal screening of asymptomatic carriage of COVID-19 in pregnant women with specific reference to the turnaround time of results, and local prevalence rates. The key findings of our study are threefold. We captured data on all attendances in a large UK maternity hospital and ours is the largest, to have reported turnaround times of less than 24 hours in over 90% of samples returned. We were also able to demonstrate a high acceptability of COVID-19 screening amongst our maternity population with only 3% declining to be tested. Thirdly, ours is the first study to demonstrate the utility of point of care testing in an unselected cohort of pregnant women attending a large UK maternity unit.

Whilst the data are reflective of our maternity service, laboratory services were also processing samples from patients attending the accident and emergency department, and medical and surgical wards within a national health service. We were still able to achieve a short turnaround time of five hours. This allowed for changes to be made within postnatal care pathway, and escalation of the use of personal protective equipment. Testing of newborns could have also been performed had it been required.

The low positive screening rate in our cohort may be partly explained by the low rates of infection in the east of England (cumulative infection rate 0.42%), in comparison to 1.27% in California and 2.12% in New York. As the pandemic evolved, advice and guidance were issued to pregnant women in the UK, who may have adopted behavioural changes that minimised interaction with the general public. Additionally, home working and minimising the commute to work could have protected them further. Interestingly, the proportion of asymptomatic carriers did not correlate with the regional infection rate. Many hospitals introduced visiting restrictions during the lockdown, and ours was no different. Partners were not allowed to attend the antenatal ward nor ultrasound scan appointments. Obstetric and non-obstetric face-to-face clinic appointments were changed to phone appointments where possible, thus reducing footfall within the hospital premises. Staff working in clinical areas were required to wear personal protective equipment in the form of a surgical mask, gloves and aprons as a minimum, and FFP3 masks for aerosol generating procedures. Thus, pregnant women attending hospital should also be reassured, not only that asymptomatic carriage of COVID-19 is low, infection within the inpatient setting is low. Whether or not this is maintained against a backdrop of rising COVID-19 infections rates is unknown.

**Strengths And Limitations**

We did not compare the test accuracy of the Samba-II machine in our population. However, this device has been tested previously in a cohort of over 1000 individuals and found to have 97% accuracy to conventional RT-PCR testing. There is no reason to believe why it should perform differently in pregnant women. In contrast, GeneXpert PCR testing has been previously been validated on a much smaller cohort of less than 50 women.[32] We did not perform radiological investigations to look for manifestations of COVID-19 pneumonia, as some others have clinical diagnosis criteria as well as laboratory diagnosis.[33, 34] Women could therefore have a negative NP or OP result for COVID-19, but have radiological changes. However, the likelihood of this is low. Although we had a high acceptability rate, we did not explore women's and staff views on screening for COVID-19, thus further research is required to evaluate this. For example, there may be a need to develop tests which are acceptable to women in labour, or training for hospital staff in contact tracing where women simply declined to be tested. In the interest of patient safety, we would suggest a conservative approach to patient pathways for women who decline testing so as not to result in contagion within the hospital setting.

**Conclusion**

The Royal College for Obstetricians and Gynaecologists in the UK have recently published guidelines on testing for asymptomatic pregnant women attending maternity units.[35] These are broadly in line with our current practice but for the type of swab being offered (conventional lab based RT-PCR as opposed to rapid testing with the SAMBA II). Owing to the variable rates of asymptomatic carriage of COVID-19 in pregnant women, and the rapid turnaround time using the SAMBA II machine, we propose the introduction of SAMBA II or other point of care testing platforms in maternity units as an accurate and acceptable test to pregnant women requiring admission.

**Abbreviations**

NP: Nasopharyngeal

OP: Oropharyngeal

CUH: Cambridge University Hospitals NHS Foundation Trust

COVID-19: Coronavirus-19

TAT: Results turnaround time

RT-PCR: Real time quantitative fluorescence polymerase chain reaction
Declarations

Details of ethics approval

This work was registered as service evaluation project (ID 3079). All women booked for maternity care at the Rosie Maternity Hospital are asked verbally whether they give their consent for data to be used for research and this is recorded in their computerised hospital records. We can therefore confirm that this is a formally approved method of consenting for use of data in research at the Rosie Maternity Unit. Identifiable data were removed from cases to ensure anonymity. Identifiable data were removed from cases to ensure anonymity. Additionally, in accordance with the United Kingdom National Health Service National Research Ethics Service guidance, neither individual informed consent nor formal research ethics committee review was required, because the study was undertaken by the direct clinical team using information collected in the course of routine care.

Consent for publication

Not applicable

Availability of data and materials

The datasets generated for the cohort study are not publically available due to current UK regulations with regards to data protection, but are available from the corresponding author on reasonable request. The datasets generated for the peak coronavirus prevalence rates can be found from international repositories listed in the references.

Competing interests

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work. Completed disclosure of interest forms are available to view online as supporting information.

Contribution to authorship

HC conceived the study. HML, RG, RH and HC designed the study. RX and HC screened titles and abstracts for inclusion and literature review. HC, RX and TP extracted and analysed data. HML helped interpret the study findings from a clinical viewpoint. HC and RX wrote the first draft, which all authors revised for critical content. All authors approved the final manuscript. HC is the guarantor. The guarantor had full access to all the data in the study, take responsibility for the integrity of the data and the accuracy of the data analysis, and had final responsibility for the decision to submit for publication. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Funding: None

Acknowledgements

We are grateful to all the pregnant women for their co-operation with COVID-19 screening during the pandemic.

References

1. WHO. Rolling updates on coronavirus disease (COVID-19). https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen.
2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England). 2020;395:497–506. doi:10.1016/S0140-6736(20)30183-5.
3. Hoffmann M, Klein-Weber H, Schroeder S, Krüger N, Herfitter T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271-280.e8. doi:10.1016/j.cell.2020.02.052.
4. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Annals of internal medicine. 2020;172:577–82. doi:10.7326/M20-0504.
5. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clinical infectious diseases. 2020;:1–8.
6. Mlcochova P, Collier D, Ritchie A, Assennato SM, Hsmillo M, Goel N, et al. Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant. Cell Reports Medicine. 2020;1.
7. Buitrago-Garcia DC, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Salanti G, et al. The role of asymptomatic SARS-CoV-2 infections: rapid living systematic review and meta-analysis. 2020.
8. Sutton D, Fuchs K, D’Alton M, Goffman D. Universal Screening for SARS-CoV-2 in Women Admitted for Delivery. New England Journal of Medicine. 2020;:1–2.
9. Assennato SM, Ritchie A V, Nadala C, Goel N, Zhang H, Datir R, et al. Performance evaluation of the point-of-care SAMBA II SARS-CoV-2 Test for detection of SARS-CoV-2. medRxiv. 2020. https://www.medrxiv.org/content/10.1101/2020.05.24.20100990v3.

10. Collier D. Dramatic impact of rapid point of care nucleic acid testing for SARS-CoV-2 in hospitalised patients: a clinical validation trial and implementation study. 2020.

11. Collier DA, Assennato SM, Warne B, Sithole N, Sharrocks K, Ritchie A, et al. Point of Care Nucleic Acid Testing for SARS-CoV-2 in Hospitalized Patients: A Clinical Validation Trial and Implementation Study. Cell Reports Medicine. 2020;1. doi:10.1016/j.xcrm.2020.100062.

12. Rivett L, Routledge M, Sparkes D, Warne B, Bartholdson J, Cormie C, et al. Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission. eLife. 2020; epub ahead of print.

13. Sridhar S, Forrest S, Kean I, Young J, Scott JB, Maes M, et al. A blueprint for the implementation of a validated approach for the detection of SARS-CoV-2 in clinical samples in academic facilities. bioRxiv. 2020;2020.04.14.041319. doi:10.1101/2020.04.14.041319.

14. Fassett MJ, Lervey LD, Yasumura L, Nguyen M, Colll JJ, Volodarsky M, et al. Universal SARS-CoV-2 Screening in Women Admitted for Delivery in a Large Managed Care Organization. American journal of perinatology. 2020. doi:10.1055/s-0040-1714060.

15. Gagliardi L, Danielli R, Suriano G, Vaccaro A, Tripodi G, Rusconi F, et al. Universal severe acute respiratory syndrome coronavirus 2 testing of pregnant women admitted for delivery in 2 Italian regions. American journal of obstetrics and gynecology. 2020;223:291–2. doi:10.1016/j.ajog.2020.05.017.

16. Yassa M, Yirmibes C, Cavusoglu G, Eksi H, Dogu C, Usta C, et al. Outcomes of universal SARS-CoV-2 testing program in pregnant women admitted to hospital and the adjuvant role of lung ultrasound in screening: a prospective cohort study. The journal of maternal-fetal & neonatal medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians. 2020;1–7. doi:10.1080/14767058.2020.1798398.

17. Prabhu M, Cagino K, Matthews KC, Friedlander RL, Glynn SM, Kubiak JM, et al. Pregnancy and postpartum outcomes in a universally tested population for SARS-CoV-2 in New York City: A prospective cohort study. BJOG: an international journal of obstetrics and gynaecology. 2020. doi:10.1111/1471-0528.16403.

18. Dória M, Peixinho C, Laranjo M, Mesquita Varejão A, Silva PT. Covid-19 during pregnancy: A case series from an universally tested population from the north of Portugal. European journal of obstetrics, gynecology, and reproductive biology. 2020;250:261–2. doi:10.1016/j.ejogrb.2020.05.029.

19. Sutton D, Fuchs K, D’Alton M, Gofman D. Universal Screening for SARS-CoV-2 in Women Admitted for Delivery. The New England journal of medicine. 2020;382:2163–4. doi:10.1056/NEJMcs2009316.

20. Buckley A, Bianco A, Stone J. Universal testing of patients and their support persons for severe acute respiratory syndrome coronavirus 2 when presenting for admission to labor and delivery at Mount Sinai Health System. American Journal of Obstetrics & Gynecology MFM. 2020;100147.

21. Vintzileos WS, Muscat J, Hoffmann E, John NS, Vertichio R, Vintzileos AM, et al. Screening all pregnant women admitted to labor and delivery for the virus responsible for coronavirus disease 2019. American journal of obstetrics and gynecology. 2020;223:284–6. doi:10.1016/j.ajog.2020.04.024.

22. London V, McLaren R, Atallah F, Cepeda C, McCalla S, Fisher N, et al. The Relationship between Status at Presentation and Outcomes among Pregnant Women with COVID-19. American journal of perinatology. 2020;37:991–4. doi:10.1055/s-0040-1712164.

23. Herraiz I, Folgueira D, Villalain C, Forcén L, Delgado R, Galindo A. Universal screening for SARS-CoV-2 before labor admission during Covid-19 pandemic in Madrid. Journal of perinatal medicine. 2020. doi:10.1515/jpm-2020-0236.

24. Naqvi M, Bunrick WM, Ozimek JA, Greene NH, Kilpatrick SJ, Wong MS. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Universal Testing Experience on a Los Angeles Labor and Delivery Unit. Obstetrics and gynecology. 2020;136:235–6. doi:10.1097/AOG.0000000000003987.

25. LaCourse SM, Kachikis A, Blain M, Simmons LE, Mays JA, Pattison AD, et al. Low prevalence of SARS-CoV-2 among pregnant and postpartum patients with universal screening in Seattle, Washington. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2020. doi:10.1093/cid/ciaa675.

26. Ceulemans D, Thijs I, Schreurs A, Verschaffen J, Lannoo L, Deprest J, et al. Screening for COVID-19 at childbirth: is it effective? Ultrasound in obstetrics & gynaecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2020;56:113–4. doi:10.1002/uog.22099.

27. Miller ES, Grobman WA, Sakowicz A, Rosati J, Peaceman AM. Clinical Implications of Universal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Testing in Pregnancy. Obstetrics and gynecology. 2020;136:232–4. doi:10.1097/AOG.0000000000003983.

28. Ochiai D, Kasuga Y, Iida M, Ikenoue S, Tanaka M. Universal screening for SARS-CoV-2 in asymptomatic obstetric patients in Tokyo, Japan. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2020;150:268–9. doi:10.1002/ijgo.13252.

29. Campbell KH, Tomatore JM, Lawrence KE, Illuzzi JL, Sussman LS, Lipkind HS, et al. Prevalence of SARS-CoV-2 Among Patients Admitted for Childbirth in Southern Connecticut. JAMA. 2020;323. doi:10.1001/jama.2020.8904.

30. Khalil A, Hill R, Ladhani S, Pattisson K, O’Brien P. Severe acute respiratory syndrome coronavirus 2 in pregnancy: symptomatic pregnant women are only the tip of the iceberg. American journal of obstetrics and gynecology. 2020. doi:10.1016/j.ajog.2020.05.005.

31. Breslin N, Baptiste C, Gyaml-Bannerman C, Miller R, Martinez R, Bernstein K, et al. Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals. American Journal of Obstetrics & Gynecology MFM. 2020;100118. doi:10.1016/j.ajogmf.2020.100118.
Table 1: Community COVID-19 prevalence and asymptomatic carriage in pregnant women
| Author  | Region/Country             | Type of study | Peak daily case load at start of the study period for relevant area | Max daily case load during study period for relevant area | Peak daily case load the end of the study period for relevant area | Number of pregnant women in study | Number tested positive | Number asymptomatic at the time of admission AND tested positive | Test positivity % | Proportion of asymptomatic test positive % |
|---------|----------------------------|---------------|-------------------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------------------|-------------------------------|----------------------|-----------------------------------------------------------------|-------------------|---------------------------------------------|
| Fassett | California, USA            | Observational retrospective study | 1261                                                             | 1921                                                 | 1921                                                              | 3923                          | 17                   | 17                                                             | 0.43              | 100.00                                      |
| Gagliardi | North of Tuscany and Liguria, Italy | Case series | 5210                                                             | 6153                                                 | 4053                                                              | 533                           | 3                    | 2                                                              | 0.56              | 66.67                                       |
| Herraiz | Madrid, Spain              | Observational retrospective study | 6278                                                             | 6740                                                 | 2610                                                              | 203                           | 2                    | 1                                                              | 0.99              | 50.00                                       |
| Naqvi   | California, USA            | Case series   | 1104                                                             | 1331                                                 | 1268                                                              | 82                            | 1                    | 0                                                              | 1.22              | 0.00                                        |
| LaCourse| Washington, USA            | Retrospective cohort | 2                                                                | 437                                                  | 314                                                               | 188                           | 5                    | 1                                                              | 2.66              | 20.00                                       |
| Ceulemans | North East Flanders, Belgium | Case series | 683                                                              | 2319                                                 | 426                                                               | 470                           | 13                   | 8                                                              | 2.77              | 61.54                                       |
| Miller  | Illinois, USA              | Case series   | 1150                                                             | 2023                                                 | 2023                                                              | 635                           | 23                   | 10                                                             | 3.62              | 43.48                                       |
| Ochiai  | Tokyo, Japan               | Retrospective analysis | 383                                                              | 743                                                  | 203                                                               | 52                            | 2                    | 2                                                              | 3.85              | 100.00                                      |
| Campbell| Connecticut, USA           | Case series   | 377                                                              | 1100                                                 | 620                                                               | 770                           | 30                   | 22                                                             | 3.90              | 73.33                                       |
| Khalil  | London, UK                 | Cohort study  | 822                                                              | 1071                                                 | 434                                                               | 129                           | 9                    | 8                                                              | 6.98              | 88.89                                       |
| Yassa   | Istanbul, Turkey           | Prospective cohort | 2131                                                             | 2936                                                 | 1035                                                              | 296                           | 23                   | 12                                                             | 7.77              | 52.17                                       |
| Prabhu  | New York, USA              | Prospective cohort | 2166                                                             | 9909                                                 | 6693                                                              | 675                           | 70                   | 55                                                             | 10.37             | 78.57                                       |
| Doria   | Senhora da Hora, Portugal  | Case series   | 302                                                              | 1516                                                 | 514                                                               | 103                           | 12                   | 11                                                             | 11.65             | 91.67                                       |
| Sutton  | New York, USA              | Cohort study  | 2166                                                             | 8775                                                 | 8775                                                              | 215                           | 33                   | 29                                                             | 15.40             | 87.60                                       |
| Buckley | New York, USA              | Case series   | 9073                                                             | 9909                                                 | 8064                                                              | 307                           | 50                   | 50                                                             | 16.29             | 100.00                                      |
| Vintzileos | New York, USA          | Retrospective cohort | 6555                                                             | 9909                                                 | 9410                                                              | 161                           | 32                   | 21                                                             | 19.88             | 65.63                                       |
| London  | New York, USA              | Retrospective cohort | 73                                                                | 9909                                                 | 8064                                                              | 156                           | 68                   | 22                                                             | 43.58             | 32.35                                       |

Data presented are in ascending order of the total proportion of pregnant women who tested positive. Data for peak daily reported COVID-19 prevalence at the start, during and end of the relevant study periods were retrieved from internationally published repositories.[36–38] This data was used to generate Figures 2 and 3. NP- Nasopharyngeal, OP- Oropharyngeal.